OMCL Stock Recent News
OMCL LATEST HEADLINES
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the BofA Securities 2024 Health Care Conference.
Omnicell (OMCL) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.39 per share a year ago.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum.
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Revenues decreased in 2023 and will continue declining in 2024 as healthcare centers are reducing their capital investments due to increased operating costs. Profit margins decreased significantly in recent quarters as a consequence of weak volumes. Recent workforce reductions should stabilize margins in the short term, and high accounts receivable should provide strong cash from operations in the coming quarters.